261 related articles for article (PubMed ID: 1687043)
21. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
[TBL] [Abstract][Full Text] [Related]
22. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
23. Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs.
Jonas M; Ambroziak U; Bednarczuk T; Nauman J
Endokrynol Pol; 2006; 57(6):596-604. PubMed ID: 17253432
[TBL] [Abstract][Full Text] [Related]
24. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
[TBL] [Abstract][Full Text] [Related]
25. Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis.
Chopra IJ; van Herle AJ; Korenman SG; Viosca S; Younai S
J Clin Endocrinol Metab; 1995 Jul; 80(7):2178-80. PubMed ID: 7608275
[TBL] [Abstract][Full Text] [Related]
26. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
Liu X; Shi B; Li H
Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
[TBL] [Abstract][Full Text] [Related]
27. Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin.
Yamaguchi Y; Inukai T; Iwashita A; Nishino M; Yamaguchi T; Shohda Y; Shimomura Y; Ohshima K; Kobayashi S; Kobayashi I
Acta Endocrinol (Copenh); 1990 Oct; 123(4):411-5. PubMed ID: 1978459
[TBL] [Abstract][Full Text] [Related]
28. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
[TBL] [Abstract][Full Text] [Related]
29. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
30. Further studies on the long-term treatment of Graves' hyperthyroidism with ipodate: assessment of a minimal effective dose.
Shen DC; Wu SY; Chopra IJ; Shian LR; Florsheim W; Solomon DH
Thyroid; 1991; 1(2):143-6. PubMed ID: 1822359
[TBL] [Abstract][Full Text] [Related]
31. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
Brokken LJ; Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
[TBL] [Abstract][Full Text] [Related]
32. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
33. Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease.
Robuschi G; Manfredi A; Salvi M; Gardini E; Montermini M; d'Amato L; Borciani E; Negrotti L; Gnudi A; Roti E
J Endocrinol Invest; 1986 Aug; 9(4):287-91. PubMed ID: 3537101
[TBL] [Abstract][Full Text] [Related]
34. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
[TBL] [Abstract][Full Text] [Related]
35. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume.
Pfeilschifter J; Ziegler R
Eur J Endocrinol; 1997 Jan; 136(1):81-6. PubMed ID: 9037131
[TBL] [Abstract][Full Text] [Related]
36. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
Buerklin EM; Schimmel M; Utiger RD
J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
[TBL] [Abstract][Full Text] [Related]
37. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
[TBL] [Abstract][Full Text] [Related]
38. Response to methimazole in Graves' disease. The European Multicenter Study Group.
Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
[TBL] [Abstract][Full Text] [Related]
39. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
[TBL] [Abstract][Full Text] [Related]
40. Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery.
Slyper AH; Wyatt D; Boudreau C
J Pediatr Endocrinol Metab; 2005 Jun; 18(6):597-602. PubMed ID: 16042328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
